List of works - Silvia Ratto-Kim

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

article

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

scientific article published in October 2014

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

scientific article published on 30 May 2016

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

scientific article published in January 2002

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

scientific article

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection

scientific article

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

article

Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals ⬇️

scientific article published on November 15, 1997

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

scientific article published in October 1997

Designing the epitope flanking regions for optimal generation of CTL epitopes.

scientific article published on 2 May 2014

Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia

article

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection.

scientific article published on 13 September 2012

Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

scientific article published on 20 December 2012

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

scientific article

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

scientific article published on 01 October 2016

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand

scientific article

Generation and Expansion of HIV-1 CD4+ Antigen-Specific T Cell Lines

article

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

scientific article published on 27 January 2016

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses

scientific article

HIV-Associated Wasting in the Era of Highly Active Antiretroviral Therapy: A Syndrome of Residual HIV Infection in Monocytes and Macrophages?

article

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E ⬇️

scientific article published on November 12, 2011

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

scientific article

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

scientific article

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons

scientific article published in June 2004

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

scientific article published on 9 January 2012

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans

scientific article published on 17 September 2007

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

scientific article

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

article

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.

scientific article published on 22 October 2009

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

article

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.

scientific article published on 22 October 2009

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

scientific article

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

scientific article

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

scientific article

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

scientific article

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

scientific article

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

scientific article published on 22 October 2009

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

scientific article published on 2 September 2017

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

scientific article published on 11 February 2016

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene.

scientific article published on 13 September 2012

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

scientific article

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

scientific article published on 3 July 2003

Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection

article

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

scientific article

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection

scientific article published in September 2012

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1

scientific article published on 2 June 2015

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

scientific article published on April 23, 2012

Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND ⬇️

scientific article published on March 13, 2013

Varicella immunity: persistent serologic non-response to immunization

article

List of works by Silvia Ratto-Kim

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals ⬇️

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia

Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection.

Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand

Generation and Expansion of HIV-1 CD4+ Antigen-Specific T Cell Lines

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses

HIV-Associated Wasting in the Era of Highly Active Antiretroviral Therapy: A Syndrome of Residual HIV Infection in Monocytes and Macrophages?

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E ⬇️

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene.

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection

TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND ⬇️

Varicella immunity: persistent serologic non-response to immunization